To compare the efficiency of brinzolamide/brimonidine fixed combination vs the dorzolamide/timolol fixed combination.
Forty-four eyes of 44 patients were divided in 2 groups treated either with dorzolamide/timolol twice a day (group A) or with brinzolamide/brimonidine twice a day (group B). Complete ophthalmic examination including Goldmann applanation tonometry was performed before treatment administration and 1, 4, 8, and 12 weeks afterwards. The intraocular pressure (IOP) was measured twice a day (morning at 9
At the end of the follow-up period (12 weeks), mean morning IOP reduction was 7.0 ± 2.8 mm Hg in group A and 8.4 ± 1.9 mm Hg in group B. A significant difference was found (p = 0.0343). In contrast, mean afternoon IOP reduction was 8.6 ± 2.7 mm Hg in group A and 7.9 ± 1.6 mm Hg in group B and no significant difference was found (p = 0.3413). No significant adverse effects were observed in either group.
Brinzolamide/brimonidine seems to be an effective and safe alternative β-blocker free fixed combination, especially for patients with comorbidities, having its own antihypertensive profile.
Eur J Ophthalmol 2017; 27(2): 160 - 163
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsVassileios Kozobolis, Georgios D. Panos, Aristeidis Konstantinidis, Georgios Labiris
- • Accepted on 12/06/2016
- • Available online on 16/07/2016
- • Published in print on 10/03/2017
This article is available as full text PDF.
- Kozobolis, Vassileios [PubMed] [Google Scholar] 1, 2, 3
- Panos, Georgios D. [PubMed] [Google Scholar] 2, * Corresponding Author (email@example.com)
- Konstantinidis, Aristeidis [PubMed] [Google Scholar] 1
- Labiris, Georgios [PubMed] [Google Scholar] 1, 2
Department of Ophthalmology, University General Hospital of Evros, Alexandroupolis - Greece
Eye Institute of Thrace, School of Medicine, University of Thrace, Alexandroupolis - Greece
Glaucoma Laser Eye Center, Athens - Greece